Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
[PDF][PDF] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong… - academia.edu
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a
Predictor of Survival Outcomes in NSCLC Patients Page 1 1 Detection and Dynamic …
Predictor of Survival Outcomes in NSCLC Patients Page 1 1 Detection and Dynamic …
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong… - Clinical Cancer …, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: Blood-based circulating-free (cf)
tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This …
tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This …
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu… - … Cancer Research: an …, 2015 - europepmc.org
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a
Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib …
Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib …
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu… - … : an official journal …, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong… - 2015 - cmuir.cmu.ac.th
© 2015 American Association for Cancer Research. Purpose: Blood-based circulating-free
(cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This …
(cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This …
[PDF][PDF] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong… - scholar.archive.org
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …
[PDF][PDF] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong… - academia.edu
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a
Predictor of Survival Outcomes in NSCLC Patients Page 1 1 Detection and Dynamic …
Predictor of Survival Outcomes in NSCLC Patients Page 1 1 Detection and Dynamic …